Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03425526 · ClinicalTrials.gov registry record · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
A Phase 1 study of Hematopoietic and Lymphoid Cell Neoplasm and Immunocompromised, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT03425526: Recruiting Phase 1 study of Hematopoietic and Lymphoid Cell Neoplasm and Immunocompromised, sponsored by M.D. Anderson Cancer Center.
NCT03425526 is a Phase 1 study of Hematopoietic and Lymphoid Cell Neoplasm and Immunocompromised that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 16 participants, below the 953-participant average among 104 other Hematopoietic and Lymphoid Cell Neoplasm trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03425526, a Phase 1 study of Hematopoietic and Lymphoid Cell Neoplasm and Immunocompromised, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial studies the side effects of allogeneic adenovirus-specific cytotoxic T lymphocytes (donor T cell therapy) and to see how well they work in treating patients with a weakened immune system (immunocompromised) and adenovirus-related disease. Allogeneic adenovirus-specific cytotoxic T lymphocytes are made from donated blood cells grown in the laboratory and are designed to kill viruses that can cause infections in immunocompromised patients with adenovirus-related disease.
Primary Outcome
Safety and tolerability will be assessed by laboratory assessments, adverse events, and serious adverse events. Adverse events will be graded by the CTCAE version 4.0. Categorical measures will be summarized using frequencies and percentages while continuous variables will be summarized using means, standard deviations, medians, minimums, and maximums.
Conditions Studied
Interventions
- BIOLOGICAL Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2018-03-15 |
| Est. Completion | 2027-01-01 |
| Phase | Phase 1 |
What NCT03425526 shows while recruiting
NCT03425526 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 953-participant average among 104 other Hematopoietic and Lymphoid Cell Neoplasm trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Hematopoietic and Lymphoid Cell Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes is the first listed.
NCT03425526 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT03425526 about?
NCT03425526 is a clinical study titled "Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease". This phase I trial studies the side effects of allogeneic adenovirus-specific cytotoxic T lymphocytes (donor T cell therapy) and to see how well they work in treating patients with a weakened immune system (immunocompromised) and adenovirus-related disease. Allogeneic adenovirus-specific cytotoxic T...
What is the current status of trial NCT03425526?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2018-03-15. Estimated completion is 2027-01-01.
What conditions does trial NCT03425526 study?
This clinical trial studies the following conditions: Hematopoietic and Lymphoid Cell Neoplasm, Immunocompromised.
What interventions are being tested in trial NCT03425526?
The interventions under investigation include: Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes (BIOLOGICAL).
Who is sponsoring clinical trial NCT03425526?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03425526 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematopoietic and Lymphoid Cell Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03425526's enrollment target sits among peer trials
16 95th of 104 higher than 10 of 104 other Hematopoietic and Lymphoid Cell Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hematopoietic and Lymphoid Cell Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia
RECRUITING · Phase 1
-
Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients
RECRUITING · Phase 1
-
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
RECRUITING · Phase 1
-
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
RECRUITING · Phase 1
-
Hu8F4 in Treating Patients With Advanced Hematologic Malignancies
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03858751 · 16 participants · Phase 1
Pharmacological Activation of HMN for OSA Aim 2
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI